| DrugRepV_1649 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | MR766 | NA | Cell viability assay | Decrease (98.7 %) | Investigational | 27571349 |
| DrugRepV_1650 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1651 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1652 | Ensulizole | NA | Sunburn | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1653 | Tenonitrozole | Antiparasitic products, Insectisides and Repellents | Protozoal infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1654 | Isoliquirtigenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1655 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Zika virus | MR766 | NA | Cell viability assay | Decrease (53.6 %) | Approved, Investigational, Vet approved | 27571349 |
| DrugRepV_1656 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1657 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Investigational | 27571349 |
| DrugRepV_1658 | Vidofludimus | NA | Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1659 | SB-366791 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1660 | Emodin | NA | Polycystic Kidney | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1661 | Diphenyl isophthalate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1662 | Benzoylpas | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1663 | Fenobam | NA | Fragile X Syndrome | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1664 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1665 | Drometrizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1666 | PHA-690509 | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | Decrease (81.9 %) | NA | 27571349 |
| DrugRepV_1667 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1668 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1669 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1670 | Cinanserin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1671 | 5-Nitro-2-(3-phenylpropylamino)benzoic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1672 | Veliflapon | NA | Myocardial infarction (Heart attack) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Phase III | 27571349 |
| DrugRepV_1673 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1674 | SIB 1893 | Neurologic-agent | Epilepsy | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1675 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1676 | Naringenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1677 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1678 | Fanetizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1679 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1680 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | Decrease (35.2 %) | Approved | 27571349 |
| DrugRepV_1681 | CAY10505 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1682 | Hesperetin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1683 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1684 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1685 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1686 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1687 | Piraxostat | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (34.7 %) | NA | 27571349 |
| DrugRepV_1688 | Albendazole oxide | NA | Parasitic infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1689 | Tyrphostin AG 494 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1690 | Genistin | Antineoplastic and Antitumor agent | Prostate cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1691 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1692 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1693 | RITA | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | Decrease (81.7 %) | NA | 27571349 |
| DrugRepV_1694 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | MR766 | NA | Cell viability assay | Decrease (51.2 %) | Approved | 27571349 |
| DrugRepV_1695 | BF-170-hydrochloride | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (65.8 %) | NA | 27571349 |
| DrugRepV_1696 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1697 | Tribromsalan | NA | Bacterial infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1698 | Pifexole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1699 | Formononetin | NA | Postmenopausal Osteopenia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1700 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1701 | Tranilast | NA | Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1702 | Benzylparaben | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Experimental | 27571349 |
| DrugRepV_1703 | 2-Ethoxylethyl-p-methoxycinnamate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1704 | Baicalein | Plant extract | Influenza | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Phase II | 27571349 |
| DrugRepV_1705 | Nemorubicin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease | NA | 27571349 |
| DrugRepV_1706 | Rutaecarpine | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1707 | MPEP | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1708 | 5,7-Dihydroxyflavone | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1709 | Pipofezine | Antidepressant | Depressive disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1710 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1711 | 2 Amino-6-nitrobenzothiazole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1712 | Malachite green oxalate | Antibacterial | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1713 | Enfenamic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1714 | Fenaminosulf | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1715 | AS-252424 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1716 | Phenserine | NA | Alzheimer's disease | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1717 | Epalrestat | Anti-diabetic | Diabetic neuropathy | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1718 | Alizarin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1719 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | Decrease (45.7 %) | Investigational | 27571349 |
| DrugRepV_1720 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | MR766 | NA | Cell viability assay | Decrease | Investigational | 27571349 |
| DrugRepV_1721 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1722 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1723 | Ensulizole | NA | Sunburn | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1724 | Tenonitrozole | Antiparasitic products, Insectisides and Repellents | Protozoal infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1725 | Isoliquirtigenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (36.3 %) | Experimental | 27571349 |
| DrugRepV_1726 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Zika virus | MR766 | NA | Cell viability assay | Decrease (62.1 %) | Approved, Investigational, Vet approved | 27571349 |
| DrugRepV_1727 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | Decrease (68.4 %) | Approved | 27571349 |
| DrugRepV_1728 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Investigational | 27571349 |
| DrugRepV_1729 | Vidofludimus | NA | Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1730 | SB-366791 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1731 | Emodin | NA | Polycystic Kidney | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1732 | Diphenyl isophthalate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1733 | Benzoylpas | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1734 | Fenobam | NA | Fragile X Syndrome | Zika virus | MR766 | NA | Cell viability assay | Decrease (60.5 %) | Investigational | 27571349 |
| DrugRepV_1735 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1736 | Drometrizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1737 | PHA-690509 | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | Decrease | NA | 27571349 |
| DrugRepV_1738 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1739 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1740 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1741 | Cinanserin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (56.9 %) | NA | 27571349 |
| DrugRepV_1742 | 5-Nitro-2-(3-phenylpropylamino)benzoic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1743 | Veliflapon | NA | Myocardial infarction (Heart attack) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Phase III | 27571349 |
| DrugRepV_1744 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1745 | SIB 1893 | Neurologic-agent | Epilepsy | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1746 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1747 | Naringenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1748 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | Decrease (35.3 %) | Approved | 27571349 |
| DrugRepV_1749 | Fanetizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1750 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1751 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1752 | CAY10505 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1753 | Hesperetin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1754 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1755 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1756 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1757 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1758 | Piraxostat | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (60.3 %) | NA | 27571349 |
| DrugRepV_1759 | Albendazole oxide | NA | Parasitic infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1760 | Tyrphostin AG 494 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (45.6 %) | NA | 27571349 |
| DrugRepV_1761 | Genistin | Antineoplastic and Antitumor agent | Prostate cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1762 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1763 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1764 | RITA | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1765 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | MR766 | NA | Cell viability assay | Decrease (97.3 %) | Approved | 27571349 |
| DrugRepV_1766 | BF-170-hydrochloride | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1767 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | Decrease (71.2 %) | Investigational | 27571349 |
| DrugRepV_1768 | Tribromsalan | NA | Bacterial infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1769 | Pifexole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1770 | Formononetin | NA | Postmenopausal Osteopenia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1771 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1772 | Tranilast | NA | Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1773 | Benzylparaben | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Experimental | 27571349 |
| DrugRepV_1774 | 2-Ethoxylethyl-p-methoxycinnamate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1775 | Baicalein | Plant extract | Influenza | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Phase II | 27571349 |
| DrugRepV_1776 | Nemorubicin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease | NA | 27571349 |
| DrugRepV_1777 | Rutaecarpine | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1778 | MPEP | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1779 | 5,7-Dihydroxyflavone | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1780 | Pipofezine | Antidepressant | Depressive disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1781 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1782 | 2 Amino-6-nitrobenzothiazole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1783 | Malachite green oxalate | Antibacterial | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Experimental | 27571349 |
| DrugRepV_1784 | Enfenamic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1785 | Fenaminosulf | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (36.7 %) | NA | 27571349 |
| DrugRepV_1786 | AS-252424 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1787 | Phenserine | NA | Alzheimer's disease | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1788 | Epalrestat | Anti-diabetic | Diabetic neuropathy | Zika virus | MR766 | NA | Cell viability assay | Decrease (82.1 %) | Investigational | 27571349 |
| DrugRepV_1789 | Alizarin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1790 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | Decrease | Investigational | 27571349 |
| DrugRepV_1791 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | MR766 | NA | Cell viability assay | Decrease (54.4 %) | Investigational | 27571349 |
| DrugRepV_1792 | Teriflunomide | Antineoplastic and Immunomodulating Agents | Multiple sclerosis (MS) | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1793 | Hydroxocobalamin | Blood and Blood Forming Organs | Vitamin B12 deficiency | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1794 | Ensulizole | NA | Sunburn | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1795 | Tenonitrozole | Antiparasitic products, Insectisides and Repellents | Protozoal infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1796 | Isoliquirtigenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1797 | Nitazoxanide | Antiparasitic products, Insectisides and Repellents | Diarrhea | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved, Investigational, Vet approved | 27571349 |
| DrugRepV_1798 | Febuxostat | Musculo-Skeletal System | Hyperuricemia | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1799 | Leflunomide | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved, Investigational | 27571349 |
| DrugRepV_1800 | Vidofludimus | NA | Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1801 | SB-366791 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1802 | Emodin | NA | Polycystic Kidney | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1803 | Diphenyl isophthalate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1804 | Benzoylpas | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1805 | Fenobam | NA | Fragile X Syndrome | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1806 | Indobufen | Blood and Blood Forming Organs | Atrial Fibrillation | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1807 | Drometrizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1808 | PHA-690509 | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1809 | Tiaprofenic Acid | Musculo-Skeletal System | Arthritic pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1810 | Flufenamic Acid | Musculo-Skeletal System | Musculoskeletal | Joint disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1811 | Vitamin B12 | Blood and Blood Forming Organs | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1812 | Cinanserin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1813 | 5-Nitro-2-(3-phenylpropylamino)benzoic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1814 | Veliflapon | NA | Myocardial infarction (Heart attack) | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Phase III | 27571349 |
| DrugRepV_1815 | Thiabendazole | Dermatologicals; Antiparasitic products, Insectisides and Repellents | Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1816 | SIB 1893 | Neurologic-agent | Epilepsy | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1817 | Anethole Trithione | Alimentary Tract and Metabolism | Xerostomia and salivary gland hypofunction | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1818 | Naringenin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1819 | Phenazopyridine Hydrochloride | Genito Urinary System and Sex Hormones | Urinary tract infection | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1820 | Fanetizole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1821 | Terazosin Hydrochloride | Genito Urinary System and Sex Hormones | Benign prostatic hyperplasia | Hypertension | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1822 | Diacerein | Musculo-Skeletal System | Osteoarthritis | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1823 | CAY10505 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1824 | Hesperetin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1825 | Suprofen | Musculo-Skeletal System | Miosis (pupil constriction) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Withdrawn | 27571349 |
| DrugRepV_1826 | Ketorolac Tromethamine | Musculo-Skeletal System | Osteoarthritis | Severe Pain | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1827 | Piperine | Anticancer | Multiple Myeloma | Deglutition Disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1828 | Pirarubicin | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1829 | Piraxostat | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1830 | Albendazole oxide | NA | Parasitic infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1831 | Tyrphostin AG 494 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1832 | Genistin | Antineoplastic and Antitumor agent | Prostate cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1833 | Fenbufen | Musculo-Skeletal System | Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis) | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved | 27571349 |
| DrugRepV_1834 | Apatinib | Antineoplastic and Immunomodulating Agents | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1835 | RITA | NA | Cancer | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1836 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Approved | 27571349 |
| DrugRepV_1837 | BF-170-hydrochloride | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1838 | OSI-930 | Anticancer | Solid tumors | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1839 | Tribromsalan | NA | Bacterial infections | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1840 | Pifexole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1841 | Formononetin | NA | Postmenopausal Osteopenia | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1842 | Ebselen | Anti-diabetic | Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1843 | Tranilast | NA | Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1844 | Benzylparaben | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Approved, Experimental | 27571349 |
| DrugRepV_1845 | 2-Ethoxylethyl-p-methoxycinnamate | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1846 | Baicalein | Plant extract | Influenza | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Phase II | 27571349 |
| DrugRepV_1847 | Nemorubicin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1848 | Rutaecarpine | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1849 | MPEP | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1850 | 5,7-Dihydroxyflavone | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1851 | Pipofezine | Antidepressant | Depressive disorders | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1852 | Flurbiprofen Axetil | Musculo-Skeletal System | Hyperalgesia | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | Investigational | 27571349 |
| DrugRepV_1853 | 2 Amino-6-nitrobenzothiazole | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1854 | Malachite green oxalate | Antibacterial | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Experimental | 27571349 |
| DrugRepV_1855 | Enfenamic Acid | NA | NA | Zika virus | MR766 | NA | Cell viability assay | Decrease (58.5 %) | NA | 27571349 |
| DrugRepV_1856 | Fenaminosulf | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect | NA | 27571349 |
| DrugRepV_1857 | AS-252424 | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1858 | Phenserine | NA | Alzheimer's disease | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1859 | Epalrestat | Anti-diabetic | Diabetic neuropathy | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1860 | Alizarin | NA | NA | Zika virus | MR766 | NA | Cell viability assay | No significant effect (0 %) | NA | 27571349 |
| DrugRepV_1861 | Dalcetrapib | Cardiovascular agents | Acute Coronary Syndrome | Zika virus | MR766 | NA | Cell viability assay | No significant effect | Investigational | 27571349 |
| DrugRepV_1862 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | MR766 (1947 Ugandan strain) | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1863 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | FSS13025 (2010 Cambodian strain) | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1864 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1865 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1866 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1867 | Emricasan | NA | Antiapoptotic and anti-inflammatory | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | Investigational | 27571349 |
| DrugRepV_1868 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 27571349 |
| DrugRepV_1869 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 27571349 |
| DrugRepV_1870 | PHA-690509 | NA | Cancer | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | NA | 27571349 |
| DrugRepV_1871 | PHA-690509 | NA | Cancer | Zika virus | NA | NA | Cell viability assay | Decrease (50 %) | NA | 27571349 |
| DrugRepV_2035 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2036 | Chlorpromazine | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2037 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2038 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2039 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2040 | Chlorpromazine | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2041 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2042 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | NA | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2043 | Chloroquine | Antiparasitic products, Insectisides and Repellents | Malaria | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2044 | Chlorpromazine | Nervous System | Schizophrenia | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2045 | Loperamide | Alimentary Tract and Metabolism | Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2046 | Lopinavir | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Severe acute respiratory syndrome coronavirus | 229E-GFP | NA | Cell viability assay | Decrease (50 %) | Approved | 24841269 |
| DrugRepV_2047 | Cilnidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (60 %) | Approved | 24841269 |
| DrugRepV_2048 | Fluoxetine Hydrochloride | Nervous System | Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Vet approved | 24841269 |
| DrugRepV_2049 | Manidipine | Cardiovascular agents | Hypertension | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Investigational | 24841269 |
| DrugRepV_2050 | Oxybutynin | Genito Urinary System and Sex Hormones | Overactive bladder | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (80 %) | Approved, Investigational | 24841269 |
| DrugRepV_2051 | Pyrimethamine | Antiparasitic products, Insectisides and Repellents | Toxoplasmosis | Acute malaria | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | No significant decrease (20 %) | Approved, Investigational, Vet approved | 24841269 |
| DrugRepV_2052 | Rifabutin | Antiinfectives For Systemic Use | Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | No significant decrease (10 %) | Approved, Investigational | 24841269 |
| DrugRepV_2053 | Rifapentine | Antiinfectives For Systemic Use | Tuberculosis | Middle East respiratory syndrome coronavirus | EMC/2012 | NA | Cell viability assay | Decrease (50 %) | Approved, Investigational | 24841269 |
| DrugRepV_3213 | Andrographolide | NA | Ulcerative colitis and Upper respiratory tract infection | Chikungunya virus | E1:226VT | NA | Cell viability assay | Decrease (25 %) | Investigational | 26384169 |
| DrugRepV_3214 | Andrographolide | NA | Ulcerative colitis and Upper respiratory tract infection | Chikungunya virus | E1:226VT | NA | Cell viability assay | Decrease (65 %) | Investigational | 26384169 |
| DrugRepV_3215 | Andrographolide | NA | Ulcerative colitis and Upper respiratory tract infection | Chikungunya virus | E1:226VT | NA | Cell viability assay | Decrease (65 %) | Investigational | 26384169 |
| DrugRepV_3356 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/WSN/33 |  | Cell viability assay | Decrease (50 %) | Approved | 30028133 |
| DrugRepV_3358 | Naproxen | Musculo-Skeletal System | Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea | Influenza virus | A/Udorn/72 | | Cell viability assay | Decrease (50 %) | Approved | 30028133 |
| DrugRepV_5488 | Candesartan cilexetil | Cardiovascular agents | Hypertension | Zika virus | PRVABC59 | NA | Cell viability assay | Decrease (50 %) | Approved | 31669333 |
| DrugRepV_5489 | Calcifediol | Alimentary Tract and Metabolism | Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, headache (continuing), increased thirst, increase in frequency of urination, irregular heartbeat, itching skin, loss of appetite, muscle pain, nausea or vomiting ( | Zika virus | PRVABC59 | NA | Cell viability assay | Decrease (50 %) | Approved, Nutraceutical | 31669333 |
| DrugRepV_5490 | Primaquine Diphosphate | Antiparasitic products, Insectisides and Repellents | Malaria | Zika virus | PRVABC59 | NA | Cell viability assay | Decrease (50 %) | Approved | 31669333 |
| DrugRepV_6479 | N-acetyl cysteine | NA | Acetaminophen poisoning | Dengue virus | NA | | Cell viability assay | Decrease (50 %) | Approved | 30928439 |
| DrugRepV_7328 | N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide | NA | NA | Japanese encephalitis virus | P3 | | Cell viability assay | Decrease (50 %) | NA | 27679979 |
| DrugRepV_7329 | N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide | NA | NA | Japanese encephalitis virus | P3 | | Cell viability assay | Decrease (50 %) | NA | 27679979 |